Michael J. Morris
迈克尔·莫里斯
MD
Chief, Genitourinary Oncology Service泌尿生殖肿瘤学服务主任
👥Biography 个人简介
Michael J. Morris is Chief of Genitourinary Oncology at MSK and a principal investigator of the landmark VISION trial, which established lutetium-177-PSMA-617 as standard of care for mCRPC. He leads translational and clinical research in radioligand therapy and PSMA-targeted approaches.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lutetium-177-PSMA-617
Led the VISION phase III trial demonstrating that 177Lu-PSMA-617 significantly improved radiographic progression-free survival and overall survival in mCRPC patients, leading to FDA approval in 2022.
Representative Works 代表性著作
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION)
New England Journal of Medicine (2021)
Pivotal phase III trial establishing 177Lu-PSMA-617 as a new standard of care for PSMA-positive mCRPC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 迈克尔·莫里斯 的研究动态
Follow Michael J. Morris's research updates
留下邮箱，当我们发布与 Michael J. Morris（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment